Humanigen — Investor Presentation (July 2021)
49 slides from Humanigen's investor presentation, Jul 14, 2021
Slide 1: Humanigen
Humanigen July 14, 2021 Humanigen
Slide 2: Cautionary Note Regarding Forward-Looking Statements
2 Cautionary Note Regarding Forward - Looking Statements All statements other than statements of historical facts contained in this presentation are forward - looking statements . Forward - looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding f
Slide 3: Agenda
3 3 2 1 Lenzilumab for COVID - 19 Emergence of Delta Variant Initial U.S. Go - to - Market Plan 4 Ex - U.S. Initial Go - to - Market Plans Humanigen Overview Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry 5 Le
Slide 4: Humanigen Today: Company Highlights
4 Humanigen Today: Company Highlights Leading expertise in Hyper - inflammation and Cytokine Storm across multiple therapeutic applications Filed for EUA in U.S., begun submission for Conditional Marketing Authorization in UK, preparing EMA submission, commercial readiness and manufacturing scale -
Slide 5: Experienced and Execution-Oriented Management
5 Experienced and Execution - Oriented Management Tim Morris, CPA – Chief Operating and Chief Financial Officer Retired CFO Iovance ; raised > $2.2Bn over 29 years Extensive deal experience with >90 transactions, combined value $4.8B 5 NDA/MAA and associated commercial prep and launch experien
Slide 6: Accomplishments and Objectives
6 Accomplishments and Objectives Next 12 months x LIVE - AIR P3 hit primary endpoint of Survival without Ventilation (“SWOV”) x LIVE - AIR manuscript published on MedRxiv (5 - 5 - 21) x ZUMA - 19 Phase 1b CAR - T data ORR 100% (4 - 19 - 21) x Application for Emergency Use Authorization - US (5 - 28
Slide 7: Clinical Pipeline
7 Clinical Pipeline Indication Phase Status Centers Partners Lenzilumab LIVE - AIR Prevention / treatment of COVID - related Hyper - inflammation / Cytokine Storm 3 Completed (520 patients) EUA submitted 24 US 11 Brazil Company sponsored ACTIV - 5/BET - B Prevention / treatment of COVID - related Hy
Slide 8: Lenzilumab Overview
8 Lenzilumab Overview Lenzilumab is administered intravenously in three equal infusions, with the full treatment course completed in a single day Humaneered ® Best - in - Class Antibody x Neutralizes GM - CSF to prevent and treat CS x Reduced immunogenicity x Highest binding affinity x Slowest off -
Slide 9: GM-CSF: A Driver of COVID-19
9 GM - CSF: A Driver of COVID - 19 T hwaites, et al. Inflammatory profiles across the spectrum reveal a distinct role for GM - CSF in severe COVID - 19. Science Immunology.2021. 6(57): eabg9873. DOI: 10.1126/sciimmunol.abg9873 • UK government - funded, independent study linked GM - CSF to severe COV
Slide 10: Agenda: Lenzilumab for COVID-19
10 3 2 1 Lenzilumab for COVID - 19 Emergence of Delta Variant Initial U.S. Go - to - Market Plan 4 Ex - U.S. Initial Go - to - Market Plans Humanigen Overview Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry 5 L
Slide 11: LIVE-AIR: Lenzilumab Phase 3 Study Design
11 LIVE - AIR: Lenzilumab Phase 3 Study Design Early intervention with lenzilumab, in addition to current standard of care, to prevent and treat CS and prevent progression to IMV and/or death • Randomized , double - blind, placebo - controlled, multi - center pivotal trial NCT 04351152 • All subject
Slide 12: Demographics and Baseline Characteristics (mITT Population)
12 Demographics and Baseline Characteristics ( mITT Population) Characteristics Lenzilumab (N=236) Placebo (N=243) Overall (N =479) Age Mean (SD) 60.5 (13.5) 60.5 (14.3) 60.5 (13.9) Median (Min - Max) 62.0 (28 - 98) 62.0 (22 - 96) 62.0 (22 - 98) < 65 years old (%) 60.2 58.4 59.3 ≥65 years old (%) 39
Slide 13: Primary Endpoint met for mITT and ITT: Survival without Ventilation
13 Primary Endpoint met for mITT and ITT: Survival without Ventilation (“SWOV”) Kaplan – Meier Estimate of Failure to Achieve SWOV Population Lenzilumab Placebo Lenzilumab vs placebo hazard ratio (95% CI) P value Absolute Δ mITT (n=479) 15.6% (11.5 – 21.0) (n=236) 22.1% (17.4 – 27.9) (n=243) 1.54 (1
Slide 14: Concomitant Therapeutics
14 Concomitant Therapeutics Therapeutic(s) (%) Lenzilumab (N=236) Placebo (N=243) Total (N=479) Remdesivir 72.1 72.8 72.4 Corticosteroids 93.7 93.8 93.7 Remdesivir & Corticosteroids 69.1 69.1 69.1 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or
Slide 15: Remdesivir + Steroids Population: Survival without Ventilation Improves
15 Remdesivir + Steroids Population: Survival without Ventilation Improves Kaplan – Meier Estimate of Failure to Achieve SWOV Population Lenzilumab (95% CI) Placebo (95% CI) Lenzilumab vs placebo hazard ratio (95% CI) P value Absolute Δ Remdesivir mITT (n=347) 15.6% (10.9 – 22.1) (n=170) 25.7% (19.8
Slide 16: Baseline CRP <150, Age <85 and Survival without Ventilation
16 Baseline CRP < 150, Age < 85* and Survival without Ventilation *Baseline CRP was evaluable in 482 patients. Based on retrospective analysis, optimal benefit for lenzilumab is seen with pa tie nts age <85 and with CRP<150 *Optimal lenzilumab patient population Kaplan – Meier Estimate of Failure to
Slide 17: Remdesivir + Baseline CRP <150, Age <85
17 Remdesivir + Baseline CRP < 150, Age < 85* Kaplan – Meier Estimate of Failure to Achieve SWOV Population Lenzilumab (95% CI) Placebo (95% CI) Lenzilumab vs placebo hazard ratio (95% CI) P value Absolute Δ CRP <150 mg/L and age <85 SWOV ITT (n=256) 10.1% (5.9 – 17.1) (n=122) 25.7% (19.1 – 34.1) (n
Slide 18: Baseline CRP <150, Age <85 and Survival without Ventilation
18 Baseline CRP < 150, Age < 85 and Survival without Ventilation Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry *Baseline CRP was evaluable in 482 patients. Based on retrospective analysis, optimal benefit for
Slide 19: Safety: Balanced Between Treatment Arms
19 Safety: Balanced Between Treatment Arms System Organ Class Preferred Term n (%) Lenzilumab N=255 Placebo N=257 Total N=512 Any AE ≥ Grade 3 68 (26.7) 84 (32.7) 152 (29.7) Respiratory, thoracic and mediastinal disorders 64 (25.1) 71 (27.6) 135 (26.4) Respiratory failure 24 (9.4) 31 (12.1) 55 (10.7
Slide 20: ACTIV-5/BET-B for the Treatment of COVID-19
20 • Lenzilumab is the third of six agents selected by NIH, the only GM - CSF molecule selected • Over 400 compounds reviewed by NIH for inclusion in ACTIV protocols • Humanigen providing lenzilumab • NIH currently executing the study; NIH and Humanigen collaborated on the protocol • Evaluation unde
Slide 21: Lenzilumab Summary
21 Lenzilumab Summary COVID - 19 • Neutralizes GM - CSF, a driver of Cytokine Storm • Prevents and treats Cytokine Storm to reduce progression to IMV and/or death • For newly hospitalized and hypoxic patients with COVID - 19 pneumonia • Convenient dosing regimen to which other treatments, including
Slide 22: Agenda: Emergence of Delta Variant
22 3 2 1 Lenzilumab for COVID - 19 Emergence of Delta Variant Initial U.S. Go - to - Market Plan 4 Ex - U.S. Initial Go - to - Market Plans Humanigen Overview Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry 5 L
Slide 23: Public Health England Risk Assessment for Delta Variant
23 Public Health England Risk Assessment for Delta Variant – July 8, 2021 Sources: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1000661/8_July_2021 _Ri sk_assessment_for_SARS - CoV - 2_variant_DELTA_02.00 - 1.pdf https://assets.publishing.service.go
Slide 24: What is a Variant of Concern (VOC)?
What is a Variant of Concern (VOC)? “ A variant for which there is evidence of an increase in transmissibility , more severe disease , significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines , or diagno
Slide 25: Agenda: Initial U.S. Go-to-Market Plan
25 3 2 1 Lenzilumab for COVID - 19 Emergence of Delta Variant Initial U.S. Go - to - Market Plan 4 Ex - U.S. Initial Go - to - Market Plans Humanigen Overview Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry 5 L
Slide 26: COVID-19 Hospital Admissions and Deaths in the US
26 In 2021 (year - to - date) there have been >1,000,000 new hospital admissions with confirmed COVID - 19 in the US¹ As of June 22, 2021, there have been 604,000+ deaths related to COVID - 19 in the US² Last year (2020) COVID - 19 was projected to Cost the US healthcare system 9.6 billion to 16.9 b
Slide 27: COVID-19 Hospitalizations Projected to Persist Beyond 2021
27 • The number of hospitalizations have already surpassed 1M in 2021, with another 350K expected this year, potentially exceeding 2020 totals 1 • Factors contributing to continued hospitalization rates include vaccine hesitancy, efficacy, variants and a lack of vaccines for certain populations 2020
Slide 28: Despite Vaccines, There Is A Sustainable Need For Effective Therapeutics
28 Similar to other viruses that have vaccines available, the need for therapeutics will continue for years to come. Despite Vaccines, There Is A Sustainable Need For Effective Therapeutics COVID - 19 has many similarities to other viruses that have been around for decades, but also several key diff
Slide 29: COVID-19 Treatment Landscape by Patient Reach and Disease Severity
29 Patient Reach Disease Severity Viral Neutralizing Antibodies Outpatient treatment Antiviral Immuno - Modulators COVID - 19 Vaccines Prophylaxis Critical patients in the ICU on mechanical ventilation and progressing rapidly 2 IMV – 2020: ~166K, 2021: ~169K, 2025: ~109K Bamlanivimab + Etesevimab Ca
Slide 30: Lenzilumab Delivered In The Hospital Setting
30 Lenzilumab - Delivered In The Hospital Setting • Medicare Part - A covers inpatient drugs • DRG prospective payments are the norm for hospitalized patients with drugs more likely bundled • Relative weight adjusted each year by CMS based on illness severity, length of hospital stay, necessary trea
Slide 31: Established Coding and Reimbursement Pathway For COVID-19
31 Established Coding and Reimbursement Pathway For COVID - 19 Recognize Healthcare System Burden ICD - 10 - Procedure Codes • 27 new codes were recently approved for COVID - 19 related conditions, circumstances, and treatments – including multiple codes for newly approved and non specific monoclona
Slide 32: Go-To-Market Strategy And Resources Intended to Scale From EUA To BLA
32 EUA Higher Lower Focus of Commercial Activity BLA EUA Digital Marketing Messaging limited to EUA fact sheet language Public Relations Drive awareness of lenzilumab availability & HGEN Targeted Field Engagement Small field team, virtual and in - person interactions Expanded Field Team, driving bra
Slide 33: Lenzilumab EUA Go-To-Market Strategy
33 lenzilumab EUA GO - TO - MARKET STRATEGY Upon receipt of Emergency Use Authorization (EUA), we are ready to launch lenzilumab with a streamlined Commercial team focused on direct engagement of high - priority accounts, National KOLs, and top hospital - based clinicians treating COVID - 19. MARKET
Slide 34: Key Account Targeting Tool and Engagement Approach
34 Key Account Targeting Tool Key Account Engagement Approach Hospital Leadership P&T Committee Physician Specialists COVID - 19 Care Team Makes business operations and purchasing decisions Assess new treatments and set Tx guidelines and protocols PUDs and IDs provide specialist consults and advisor
Slide 35: Agenda: Ex-U.S. Initial Go-to-Market Plans
35 3 2 1 Lenzilumab for COVID - 19 Emergence of Delta Variant Initial U.S. Go - to - Market Plan 4 Ex - U.S. Initial Go - to - Market Plans Humanigen Overview Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry 5 L
Slide 36: Established Manufacturing Agreements for Lenzilumab
36 Established Manufacturing Agreements for Lenzilumab Manufacturing Partners Bioreactor (BDS) batches • Catalent - Madison, WI • Catalent - Bloomington, IN • ThermoFisher - St. Louis, MO • Avid Biosciences - Tustin, CA • Chime – China (ex - US) BDS Vials Cardinal Health Bulk Drug Substance Drug Pro
Slide 37: Lenzilumab Rest of World Opportunities
37 Lenzilumab Rest of World Opportunities COVID cases currently approaching 185 million 1 • Ex - US countries represent 80% of cases, with 50 countries having at least 400,000 cases (20,000 hospitalized patients) 1 HGEN EUA reviews/filings in US, UK, EMA underway, reviewing potential for EUA in Indi
Slide 38: COVID-19 Cases Continue in the UK and Europe
38 COVID - 19 Cases Continue in the UK and Europe United Kingdom 1 Adults Vaccinated with 1 dose 87% Adults Vaccinated with 2 doses 66% Prior seven days COVID cases 221,052 Hospitalizations 3,081 Deaths 203 Increase over prior seven - day period COVID cases 27% ↑ Hospitalizations 56% ↑ Deaths 66% ↑
Slide 39: MHRA Approval Process for COVID-19 Therapeutics in the UK
39 MHRA Approval Process for COVID - 19 Therapeutics in the UK • Guidance published in May 2020 for medicines to treat COVID - 19 1 in the United Kingdom • MHRA working with Department of Health and Social Care (DHSC) • Flexibility allows to request for Fast Tracking of review 2 Lenzilumab in the UK
Slide 40: EMA Approval Process for COVID-19 Therapeutics
40 European Medicines Agency (EMA) Approval Process for COVID - 19 Therapeutics • Rapid review procedures established by EMA in May 2020 to provide conditional approval of medicines for COVID - 19 1 • Pandemic Task Force (COVID - ETF) created by EMA to work with CHMP specifically for COVID - 19 • Mo
Slide 41: Agenda: Lenzilumab for aGvHD, CAR-T, and CMML
41 3 2 1 Lenzilumab for COVID - 19 Emergence of Delta Variant Initial U.S. Go - to - Market Plan 4 Ex - U.S. Initial Go - to - Market Plans Humanigen Overview Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry 5 L
Slide 42: ZUMA-19 Phase 1b Results
42 ZUMA - 19 Phase 1b Results • At the recommended Phase 2 dose, lenzilumab in combination with CAR - T, demonstrated a 100% objective response rate (ORR) • No severe cytokine release syndrome or severe neurotoxicity • Lenzilumab reduced IL - 6, CRP, ferritin, MCP - 1, IL - 8, and IP - 10 (CXCL - 10
Slide 43: Significant CAR-T Market Growth Expected
43 Significant CAR - T Market Growth Expected The C AR - T market is expected reach $6.1 billion by 2030 1 There are barriers to uptake of CAR - T therapy 2 A survey showed one - third of physicians think toxicity might hinder their prescribing of CAR - T therapy Over 60% suggested that patients sho
Slide 44: CMML: PREACH-M Trial
44 CMML: PREACH – M trial ( PREcision Approach to CHronic Myelomonocytic Leukemia) CMML is an aggressive Cancer 1 12.8 cases per 100,000 persons per year 2 Incidence higher with age 1 In spite of advances, survival remains dismal 1 Effective therapies are needed to improve outcomes 1 1. Murthy et al
Slide 45: Acute Graft vs. Host Disease: a Growing Market with Significant Unmet Need
45 Acute Graft vs. Host Disease ( aGvHD ): a Growing Market with Significant Unmet Need Care for initial aGvHD is Steroids 2 - 6 Approximately half of patients will not achieve an adequate response to steroids 2 - 6 Patients with steroid resistant aGvHD have a poor prognosis with mortality rates ove
Slide 46: Activity in Glioblastoma Multiforme
46 MRI ( T1 + C) 89 Zr - ifabotuzumab PET 18 F - FDG PET 89 Zr - ifabotuzumab Targeting of Tumor Microenvironment Phase 1 study to start Q4 2021 looking at broader tumour activity including: Breast Lung Colorectal Pancreas Whole body biodistribution images showed no specific normal tissue uptake of
Slide 47: Agenda: Balance Sheet and 12-month Goals
47 3 2 1 Lenzilumab for COVID - 19 Emergence of Delta Variant Initial U.S. Go - to - Market Plan 4 Ex - U.S. Initial Go - to - Market Plans Humanigen Overview Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry 5 L
Slide 48: Financial Overview
48 Financial Overview Current Balance (M) • Cash and cash equivalents* $93 • Proforma post Q1 with proceeds* $187 • Proforma shares outstanding* 59 Strong Balance Sheet Supports Commercial and Manufacturing Scale - up *Based on 10Q filing as of March 31, 2021 Hercules Loan Facility (M) • Total credi
Slide 49: Goals for Next 12 Months
49 Goals for Next 12 Months □ Commercial scale manufacture of lenzilumab □ Commence commercialization in countries where lenzilumab use authorized/approved □ Announce data from ACTIV - 5/BET - B □ Initiate Phase 2/3 CMML study □ Initiate Phase 2/3 acute GvHD study □ Initiate Phase 2 potential regist